Skip to main content
Caplight Logo









OncoDNA

OncoDNA

Private
BelgiumHealthcare & Life Scienceshttps://oncodna.com/

Last Round

Grant

Jan 17, 2024

Total Funding Raised

$35.77M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

OncoDNA is a biotechnology company that provides genomic and theranostic testing services and software to aid oncologists in making personalized treatment decisions.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

precision medicinegenomic profilingliquid biopsyclinical decision supportCDSSnext-generation sequencingNGSmolecular diagnosticscancer diagnosticsbioinformaticsoncology softwareai-driven diagnosticscompanion diagnosticspersonalized cancer caretheranosticsmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OncoDNA Comparables

Compare OncoDNA with similar companies based on industry and business-model similarity.

OncoDNA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Strata Oncology
79%
Lucence
78%
Hedera Dx
78%

OncoDNA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 17, 2024
Series CJul 3, 2023
Series BFeb 14, 2020
Series ASep 2, 2016

Key People

Founding team and executive leadership

Jean-Pol Detiffe

Founder, Chief Strategy Innovation Officer, Board Member OncoDNA Integragen

Founding Team

OncoDNA Investors

Notable investors and investment history

OncoDNA investors
InvestorRounds
Federal Holding and Investment CompanySeries B, Series C
Ackermans & van HaarenSeries B, Series C, Series A
Verve VenturesSeries B
InventuresSeries A, Series B
Société Régionale d'Investissement de WallonieSeries A, Series B
Wallonie EntreprendreSeries C
Vesalius Biocapital PartnersSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 101% MoM, reaching 4.2K.

  • Mar 1, 2026

    Upcoming launch of 'fragmentomics' liquid biopsy assay in March 2026.

OncoDNA Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

OncoDNA Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about OncoDNA's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelgium
Employee Range47
Year Founded2012
Last FundingJan 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?